2UK prospective diabetes study(UKPDS) group Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes( UKPDS 33 ). Lancet ,2007:352 - 837.
10Larkings GR, Dunlop ME. The link between hypergly caemia and diabetic nephropathy. Diabetologia,2006,35:499.
二级参考文献20
1Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs, 1997,6:1025-1040.
2Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes : a 6-month randomized placebo-controlled dose-response study. Diabetes Care, 2000,23 : 1605-1611.
3Grinsell JW, Lardinois CK, Swislocki A, et al. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensitve rat, Am J Hypertens, 2000,13:370-375.
4Hiruse H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism,2002,51:314-317.
5Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am, 1997,26:553-573.
6Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of patients with type 2 diabetes: a randomized, placebocontrolled study. Am J Med, 2001,111:10-17.
7The Scandinavian Simvastatin Survival Study Group. Ran-domised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344(5):1383
8Golbourt U, Brunner D, Behar RH. Baseline characteristics of patients participating in the bezafibrate infarction prevention (BIP) study. Eur Heart J, 1998, 19(Suppl H): H42
9Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low lipoprotein particle size and relationship of lipoprotein variables to progression of coronary artery disease in the bezafibrate coronary atherosclerosis internation trail (BECAIT). J Am Coll Cardio, 1998, 32(6):1648
